abstract |
The present invention provides for monoclonal anti-IFITM2 and anti-IFITM3 antibodies or a fragment thereof, pharmaceutical compositions comprising said antibodies and its use in the treatment of viral infections, preferably of SARS-CoV-2 infection in host human cells. |